![1.jpg 1.jpg](/SupplyImg/2024-01-29/6384213701779533871764459.jpg)
FCRL5產品信息
英文名稱:Fc receptor-like protein 5
中文名稱:Fc受體樣蛋白5
靶點別稱:BXMAS1, CD307, CD307e, FCRH5, IRTA2, PRO820
物種:Human / Mouse / Cynomolgus
標簽:His Tag & Avi Tag / His Tag
屬性:Protein
標記:Biotin-labeled / Unconjugated
內毒素(Endotoxin)
Less than 0.01 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
1. -20°C to -70°C for 12 months in lyophilized state;
2. -70°C for 3 months under sterile conditions after reconstitution.
![2.jpg 2.jpg](/SupplyImg/2024-01-29/6384213702922199235463841.jpg)
FCRL5分子背景
May be involved in B-cell development and differentiation in peripheral lymphoid organs and may be useful markers of B-cell stages. May have an immunoregulatory role in marginal zone B-cells.
關鍵字: FCRL5;FCRL5蛋白;Fc受體樣蛋白5;CD307;CD307蛋白;
百普賽斯集團ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產業(yè)領域提供關鍵生物試劑產品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產基地。目前累計服務客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。